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Background: The incidence of transfusion-transmitted malaria is very low in non-endemic countries due to strict
donor selection. The optimal strategy to mitigate the risk of transfusion-transmitted malaria in non-endemic
countries without unnecessary exclusion of blood donations is, however, still debated and asymptomatic carriers of
Plasmodium species may still be qualified to donate blood for transfusion purposes.
Case description: In April 2011, a 59-year-old Dutch woman with spiking fevers for four days was diagnosed with
a Plasmodium malariae infection. The patient had never been abroad, but nine weeks before, she had received red
blood cell transfusion for anaemia. The presumptive diagnosis of transfusion-transmitted quartan malaria was made
and subsequently confirmed by retrospective PCR analysis of donor blood samples. The donor was a 36-year-old
Dutch male who started donating blood in May 2006. His travel history outside Europe included a trip to Kenya,
Tanzania and Zanzibar in 2005, to Thailand in 2006 and to Costa Rica in 2007. He only used malaria prophylaxis
during his travel to Africa. The donor did not show any abnormalities upon physical examination in 2011, while
laboratory examination demonstrated a thrombocytopenia of 126 × 109/L as the sole abnormal finding since 2007.
Thick blood smear analysis and the Plasmodium PCR confirmed an ongoing subclinical P. malariae infection.
Chloroquine therapy was started, after which the infection cleared and thrombocyte count normalized. Fourteen
other recipients who received red blood cells from the involved donor were traced. None of them developed
malaria symptoms.
Discussion: This case demonstrates that P. malariae infections in non-immune travellers may occur without
symptoms and persist subclinically for years. In addition, this case shows that these infections pose a threat to
transfusion safety when subclinically infected persons donate blood after their return in a non-endemic malaria
region.
Since thrombocytopenia was the only abnormality associated with the subclinical malaria infection in the donor,
this case illustrates that an unexplained low platelet count after a visit to malaria-endemic countries may be an
indicator for asymptomatic malaria even when caused by non-falciparum Plasmodium species.
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Transfusion-transmitted malaria (TTM) was first de-
scribed in 1911 [1]. The most recent publication on glo-
bal incidence of TTM, based on data from 1911 to 1979
[2], suggests that the incidence of TTM is about 145 re-
ported cases per year, mostly confined to endemic coun-
tries. The relatively high likelihood of TTM via donor
blood in sub-Saharan African countries is illustrated by
a median prevalence of malaria, determined by micro-
scopic evaluation of thick blood smears, of 10.2% (range:
0.7% in Kenya to 55% in Nigeria) in donor blood sam-
ples [3]. In endemic countries differentiating cases of
TTM from natural infections is a challenge as malaria,
occurring post-transfusion, can be the result of either a
natural infection or transfusion-transmitted. Hence, the
number of TTM in endemic countries is unquestionably
under-reported. In striking contrast, in non-endemic
countries the incidence of TTM is low, due to strict
donor selection. Three cases were reported in Canada
between 1994 and 1999 [4], 14 in the USA between
1990 and 1999 [5] and two in the UK since 1996 [6]. In
the past decade, two cases were reported from other
European countries, both with fatal consequences for
the recipient [7,8].
The optimal strategy to minimize the risk of TTM in
non-endemic countries without unnecessary exclusion of
blood donations is still a matter of debate. Reesink and
colleagues provided an excellent overview of current
strategies in a number of (mainly European) non-
endemic countries [9,10]. In short, most countries apply
a strict donor deferral system based on travel history.
However, this strategy is not optimal because many
healthy donors are deferred unnecessarily, leading to do-
nation loss, and lengthy deferrals may discourage donors
to return at all [1]. Despite these strict donor deferral
systems, some asymptomatic carriers of Plasmodium
spp. may still be accepted for blood donation, and there-
fore the possibility of TTM is not completely excluded
([11,12] and this case report).
Potential donor exposure to acquisition of malaria par-
asites is an increasing problem due to the substantial rise
in global travelling and immigration. Therefore, it is
more challenging than ever to ensure that the blood
supply in non-endemic areas is devoid of potential mal-
aria infections. Donor selection measures, such as
geographical-risk questions in order to identify the do-
nors at risk and to temporarily defer them, have been
implemented by the blood bank community. In addition,
some blood transfusion services in non-endemic areas
implemented laboratory testing for shortened deferrals
and/or to further reduce the risk of TTM. Donors can
be tested by thick blood smear examination, malarial
antibody testing and Plasmodium DNA detection by
PCR [1,13,14]. It is widely accepted that none of thesestrategies is perfect, due to either lack of test sensitivity
or unfavorable cost efficiency. The optimal approach for
a given location will vary according to the background
level of malaria risk faced by the donor and recipient
population, in combination with the resources available.
Case presentation
A case is presented of transfusion-transmitted Plasmo-
dium malariae infection from a long-term asymptom-
atic, non-immune traveller who had not experienced any
clinical malaria before.
The recipient
A 59-year-old Dutch woman was seen at the outpatient
clinic of the Leiden University Medical Centre (LUMC)
on April 14th 2011, because of spiking fevers for four
days. Two months before, on February 14th, she under-
went coronary-artery bypass surgery because of symp-
tomatic coronary artery disease (Table 1). She had been
feeling tired and nauseous and suffered from a non-
productive cough and chest pain on deep inspiration
since. She presented with daily fevers up to 38.8°C ac-
companied by chills, headache, nausea, and night sweats.
Upon physical examination no abnormalities were
found. Laboratory tests revealed leukocytopaenia (3.6 ×
109/L) and thrombocytopenia (71 × 109/L). In the per-
ipheral blood smear malaria parasites were seen which
were subsequently identified as P. malariae by morph-
ology and PCR. The parasitaemia was 2%. The patient
was treated with chloroquine (25 mg/kg) and recovered
completely.
The patient had never been abroad, neither had she
recently been near an international airport. During her
admission in February 2011, she had received one unit
of packed red blood cells immediately after surgery.
Hence, the presumptive diagnosis of transfusion-
transmitted quartan malaria was made.
The donor
The Dutch blood bank was notified immediately about
the presumptive diagnosis of TTM, after which the in-
volved donor was informed and donation records were
retrieved. Stored plasma from the involved donation as
well as subsequent collected blood was examined for
malaria (Tables 1 and 2). Thin and thick blood smears
were negative, but immune fluorescence assay (IFA) was
weakly positive and the sensitive Plasmodium-specific
semi-quantitative real-time PCR showed a weak, though
positive signal for P. malariae (Ct-value 38), confirming
the persistent, asymptomatic P. malariae infection in
the donor (Table 2).
The blood donor was then referred to the Rotterdam
Harbour Hospital in August 2011. The donor was a 36-
year-old Dutch male without relevant medical history. In
Table 1 Overview of most relevant events
Date Donor/Recipient Event
August 2005 Donor Visit to Kenya, Tanzania and Zanzibar
3 April 2006 Donor First visit to blood bank for examination and giving blood samples for testing
4 May 2006 Donor Blood donation #1
2 August 2006 Donor Blood donation #2
Aug – Sept 2006 Donor Visit to Thailand (only to low risk areas for malaria, no precautions required)
9 November 2006 Donor Blood donation #3
27 February 2007 Donor Blood donation #4 at a thrombocyte count of 141 × 109/L
22 May 2007 Donor Blood donation #5 at a thrombocyte count of 94 × 109/L
29 May 2007 Donor Informed about thrombocytopenia; referred to GP
14 August 2007 Donor Blood donation #6
September 2007 Donor Visit to Costa Rica
26 May 2008 Donor Blood donation #7
25 August 2008 Donor Blood donation #8
17 November 2008 Donor Blood donation #9
11 February 2009 Donor Blood donation #10
8 June 2009 Donor Blood donation #11
3 December 2009 Donor Blood donation #12
1 March 2010 Donor Blood donation #13
10 May 2010 Donor Blood donation #14
9 February 2011 Donor Blood donation #15
14 February 2011 Recipient Coronary-artery bypass surgery and transfusion of red blood cell concentrate from blood donation #15
14 April 2011 Recipient Diagnosis P. malariae infection
14 April 2011 Donor Informed about post-transfusion malaria infection in recipient
7 June 2011 Donor Blood collection for malaria tests
23 June 2011 Donor First laboratory evidence for subclinical P. malariae infection in specimen collected on 7 June 2011
17 August 2011 Donor First visit to Harbour hospital and initial examination
8 November 2011 Donor Second visit to Harbour hospital; confirmation of on-going, subclinical P. malariae infection
10 November 2011 Donor Start oral chloroquine treatment
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chills in the past five years, nor did he take any medica-
tion. The donor had a secretarial job and lived about
50 km from the nearest international airport. He started
donating blood in May 2006 and had given 15 whole
blood donations until 2011 (Table 1). His travel history
outside Europe included a trip to Kenya, Tanzania and
Zanzibar in 2005, for which he had used atovaquone/
proguanil as malaria prophylaxis. In 2006 and 2007 he
visited Thailand and Costa Rica, respectively. On both
occasions he did not use malaria chemoprophylaxis. Ac-
cording to the donor, he only stayed in low risk areas for
malaria in Thailand. Therefore, the donor was only de-
ferred from blood donations for six months following
his visit to Africa and Costa Rica, according to the Euro-
pean Union directive (Figure 1) [15].
Physical examination showed no abnormalities and the
spleen was not enlarged (11.5 cm) on abdominal ultrasoundexamination. Laboratory examination demonstrated a
thrombocytopenia of 126 × 109/L, hemoglobin 9.6 mmol/L,
leucocyte count of 4.1 × 109/L and lactate dehydrogenase
(LDH) 163 U/L. Standard malaria diagnostics by a malaria
rapid test, thin and thick blood smears as well as quantita-
tive buffy coat (QBC) analysis were negative. However,
upon his second visit in November 2011, a single malaria
parasite was detected after meticulous investigations of over
five thick and five thin blood smears (Figure 2). A subse-
quently ordered Plasmodium-specific semi-quantitative
real-time PCR was positive for P. malariae (Ct-value 37),
confirming an ongoing subclinical P. malariae infection.
The high Ct-values (37-38) observed in the subsequent
blood specimens of the donor are close to the detection
level of these tests and correspond to extremely low para-
site numbers in the order of 1-100 parasites per mL.
Plasma and thrombocytes from the donor were never
used for transfusion, but red blood cells were transfused
Table 2 Overview of relevant laboratory test results of donor
Collection
date
Laboratory test Result Specimen
27 February
2007
Thrombocyte count 141 × 109/L Fresh blood
22 May 2007 Thrombocyte count 94 × 109/L Fresh blood
9 February
2011
Plasmodium species PCR * Negative Stored plasma
Malaria serology by ELISA * Negative (0.36, cut off <1.0) Stored plasma
Malaria serology by immunofluorescence assay (IFA) * Positive (1:40, cut-off <1:40) Stored plasma
7 June 2011 Plasmodium genus PCR Positive for Plasmodium spp. EDTA-blood
Malaria serology by immunofluorescence assay (IFA) Positive (1:160, cut-off <1:40) Serum
Plasmodium species PCR Positive for P. malariae EDTA-blood
17 August
2011
Thrombocyte count 126 × 109/L Fresh blood
Thick blood smear, QBC, malaria antigen test Negative Fresh blood
8 November
2011
Thrombocyte count 128 × 109/L Fresh blood
QBC, malaria antigen test, thin blood smear, malaria serology (ELISA) Negative Fresh blood
Thick blood smear One structure suspected for P.
malariae
Fresh blood
Plasmodium species PCR Positive for P. malariae Fresh blood
Plasmodium species PCR Positive for P. malariae Bone marrow
biopsy
Leishmania spp. PCR Negative Bone marrow
biopsy
26 November
2011
Thrombocyte count 144 × 109/L Fresh blood
1 December
2011
Thrombocyte count 157 × 109/L Fresh blood
12 July 2012 Thrombocyte count 139 × 109/L Fresh blood
Thick and thin blood smears, QBC, malaria antigen test, malaria serology (ELISA),
Plasmodium species PCR
Negative Fresh blood
6 March 2013 Thrombocyte count 209 × 109/L Fresh blood
Thick and thin blood smears, QBC, malaria antigen test, malaria serology (ELISA),
Plasmodium species PCR
Negative Fresh blood
The tests were performed in the following laboratories: Diagnostic Services, Sanquin Blood Supply Foundation, Amsterdam (2007 and malaria serology by ELISA
first half 2011); Dept. Medical Microbiology, University Medical Centre St Radboud, Nijmegen, and/or Dept. Parasitology, Leiden University Medical Centre, Leiden
(first half 2011); the Harbour Hospital Laboratory, Dept. Medical Microbiology and Infectious Diseases and Clinical Chemistry, Erasmus University Medical Centre
and Harbour Hospital, Rotterdam (from August 2011 onwards). Tests marked by an *indicate results of tests performed retrospectively in May to July 2011 on
materials collected on 9 February 2011.
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oped malaria symptoms after transfusion. When the look-
back procedure was performed, already 11 recipients had
died of reasons other than malaria. The remaining three re-
cipients were invited for a thorough malaria screening. One
recipient was tested negative for malaria by both serology
and real-time PCR. The two other recipients had no clinical
signs of malaria and declined the invitation.
In retrospect, laboratory screening by the blood bank
upon application of the donor to volunteer for platelet do-
nations by aphaeresis, already revealed an unexplained
thrombocytopenia (94 × 109/L) in February and May 2007.
The blood bank staff then advised the donor to consult his
general practitioner. To exclude other causes of
thrombocytopenia apart from malaria, bone marrowmorphology was examined, which demonstrated no abnor-
malities. In addition, no platelet antibodies were detected
and the donor had normal thrombopoietin levels (13 E/mL;
n = 4-32). All results together with the longstanding
thrombocytopenia and travel history demonstrated that the
donor must have had a subclinical P. malariae infection for
at least four years and that the infection was most probably
acquired during his travel through Kenya, Tanzania and
Zanzibar in 2005 or during his visit to Thailand in 2006.
He was treated orally with chloroquine 600 mg followed by
a dose of 300 mg after six, 24 and 48 hours, respectively.
On follow-up, his platelet count quickly normalized
(Figure 2) and all malaria tests (thick and thin blood
smears, QBC, malaria rapid tests, PCR, and serology)
turned negative (Table 2).
Figure 1 Time line of important donor events. Blood donations by the donor are indicated by open triangles. Visits to Africa, Thailand and
Costa Rica are indicated by #, * and +, respectively. Deferral periods are indicated by grey bars. The solid line connects the platelet count
numbers in course of time. The dashed line indicates the lower reference value for normal thrombocyte concentrations. The arrow indicates the
start of oral chloroquine treatment.
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This case of TTM is remarkable, not only for being the
first TTM case in the Netherlands in 43 years [16], but
also because the donor was a non-immune traveller
from a non-endemic country who never suffered from
malaria and was without any symptoms for at least four
years after acquisition of the P. malariae infection. Para-
site counts in P. malariae are usually low, due to the
low number of merozoites produced per asexual cycle in
the erythrocyte, the slow replication cycle of 72 hours in
erythrocytes and the preference of the parasite to de-
velop in older erythrocytes. These factors usually allow
for earlier development of immunity by the human host
if left untreated. Blood stage P. malariae can persist for
extremely long periods, often, it is believed, for the life
of the human host [17]. Although subclinical malaria isFigure 2 Giemsa-stained thick blood smear from the donor
with a structure suspected for a malaria parasite.relatively common in endemic countries [18], asymp-
tomatic P. malariae infections in non-immune travellers
are probably very rare, as reports of experimental P.
malariae infections for the treatment of neurosyphilis
patients between 1940 and 1963 recorded only a single
patient without fever out of 69 infected patients [17,19].
Thrombocytopenia is a common feature of malaria,
occurring in 24-93% of cases of acute disease [20,21]. In
asymptomatic Plasmodium spp. carriers thrombocyte
numbers are unknown, although one paper from Nigeria
showed that asymptomatic carriers of Plasmodium spp.
had a moderately lower platelet count than non-
parasitaemic subjects [22]. The only abnormality in the
donor in this case was a thrombocytopenia that was first
observed in May 2007 and persisted until the malaria in-
fection was cleared by chloroquine treatment. This now
suggests that thrombocytopenia may be an indicator for
asymptomatic infections by Plasmodium species other
than P. falciparum as well. Further studies are needed to
determine whether, and to what extent, this finding
holds true in a larger group of asymptomatic carriers of
Plasmodium spp.
For asymptomatic visitors to malaria-endemic areas,
other than ex-residents and individuals with a history of
malaria infection, the European Union directive for tech-
nical requirements for blood and blood components states
that they shall be excluded from blood donation for six
months after leaving the endemic area [15]. The donor in
this case was qualified to donate blood according with the
provisions of this directive (Table 1). This illustrates that a
donor deferral policy based on geographic-risks reduces the
risks of TTM, but cannot prevent incidents from occurring.
It is noteworthy that the most commonly used serological
test for screening donors for IgG antibodies to Plasmodium
Brouwer et al. Malaria Journal 2013, 12:439 Page 6 of 6
http://www.malariajournal.com/content/12/1/439spp., the Malaria Total Antibody EIA kit (Lab21, Healthcare
Ltd., Kentford, UK), used by the Dutch blood bank as well
as by several other blood transfusion services in non-
endemic countries to shorten deferral periods for ex-
residents of malaria endemic areas and for individuals with
a history of malaria, did not detect this asymptomatic mal-
aria infection in the donor. This test was performed retro-
spectively (Table 2).
Only expensive methods, such as the sensitive serological
immune fluorescence assay (IFA) and real-time PCR ana-
lysis (Table 2), did detect the asymptomatic P. malariae in-
fection in the donor. As long as effective methods for
pathogen inactivation of red cell units or whole blood are
not available, cases of TTM can continue to occur in areas
that are not endemic for malaria, irrespective of the safety
measures currently adopted by the blood bank community.
Conclusion
This case demonstrates that asymptomatic chronic P.
malariae infections can occur in non-immune persons after
a visit to malaria-endemic areas and thus pose a continued
threat to transfusion safety. Since thrombocytopenia was
the only abnormality associated with this asymptomatic P.
malariae infection in the donor, an unexplained low plate-
let count may be an indicator for asymptomatic malaria
even when caused by non-falciparum Plasmodium species.
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